Bharat Immunological Biological Corporation Ltd vs Biofil Chemicals Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Bharat Immunological & Biological Corporation Ltd is ₹ 17.47 as of 18 May 15:30 . The P/E Ratio of Bharat Immunological & Biological Corporation Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Biofil Chemicals & Pharmaceuticals Ltd changed from 86.4 on March 2021 to 121 on March 2025 . This represents a CAGR of 6.97% over 5 years The Market Cap of Bharat Immunological & Biological Corporation Ltd changed from ₹ 196.47 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Market Cap of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 106.81 crore on March 2021 to ₹ 66.92 crore on March 2025 . This represents a CAGR of -8.93% over 5 years The revenue of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.93 crore as compare to the Sep '25 revenue of ₹ 13.6 crore. This represent the decline of -93.16% The ebitda of Bharat Immunological & Biological Corporation Ltd for the Dec '25 is ₹ 0 crore as compare to the Sep '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Biofil Chemicals & Pharmaceuticals Ltd for the Dec '25 is ₹ 0.17 crore as compare to the Sep '25 ebitda of ₹ 0.18 crore. This represent the decline of -5.56% The net profit of Bharat Immunological & Biological Corporation Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Biofil Chemicals & Pharmaceuticals Ltd changed from ₹ 0.17 crore to ₹ 0.08 crore over 7 quarters. This represents a CAGR of -35.00% The Dividend Payout of Bharat Immunological & Biological Corporation Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Dividend Payout of Biofil Chemicals & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Bharat Immunological & Biological Corporation Ltd

The Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL) is a Central Public Sector Unit, under the Department of Biotechnology, Ministry of Science and Technology.
BIBCOL was incorporated in 1989.
The Company is engaged in the manufacture of Oral Polio Vaccine (OPV) , Zinc Tablets and Diarehha management Kit and BIB Sweet Tablets. The company's manufacturing unit is located in Bulandshahr Dist., Uttar Pradesh.
BIBCL installed a plant of 100 mln units.
Commercial production of the OPV started from Jan'96. The company has received firm orders for supply of OPV from the Ministry of Health and Family Welfare, Government of India, for use in the national immunisation programme.

About Biofil Chemicals & Pharmaceuticals Ltd

Biofil Chemicals & Pharmaceuticals Limited (BCPL) was incorporated as a Private Limited Company on 4 Jan.'85 for manufacturing and trading of Pharmaceuticals products.
Later on, the Company was converted into a Public Limited Company on 7 May '92.
The Company deals in providing job work facility in respect of manufacturing of pharmaceuticals drug.
It runs the business via two unit viz Pharmaceutical Division & Chemicals Division. In Feb.'96, the company had come out with a rights-cum-public issue at a premium of Rs 7.50 and at a premium of Rs 12.50 respectively, both aggregating Rs 23.21 cr, to part-finance its expansion and diversification into bulk drugs and pharmaceutical formulations.
The company currently manufactures pharmaceutical formulations like injections, capsules, eye-drops and dry syrups at its plant located in Indore.

FAQs for the comparison of Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd

Which company has a larger market capitalization, Bharat Immunological & Biological Corporation Ltd or Biofil Chemicals & Pharmaceuticals Ltd?

Market cap of Bharat Immunological & Biological Corporation Ltd is 75 Cr while Market cap of Biofil Chemicals & Pharmaceuticals Ltd is 52 Cr

What are the key factors driving the stock performance of Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd?

The stock performance of Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd?

As of May 18, 2026, the Bharat Immunological & Biological Corporation Ltd stock price is INR ₹17.47. On the other hand, Biofil Chemicals & Pharmaceuticals Ltd stock price is INR ₹32.22.

How do dividend payouts of Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Bharat Immunological & Biological Corporation Ltd and Biofil Chemicals & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.